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86S Abstracts June Supplement 2014Methods: The 2-hour and 24-hour attachment of
Staphylococcus aureus TCH1516 and Pseudomonas aerugi-
nosa PA01-UW was determined on polytetraﬂuoroethy-
lene, Dacron, nitinol, cobalt chromium, and Viabahn
endoprosthesis. Individually and in combination, concen-
trations at 104, 105, 106, 107, and 108 were tested on
2-mm sections of each graft. After each time interval, the
prosthetics were rinsed to remove nonattached bacteria,
sonicated to release the attached bacteria, spiral plated,
and then analyzed for the attached concentration.
Results: After 2 hours, there was a signiﬁcant differ-
ence in the median attachment rates on Dacron (14%)
compared with nitinol (2.1%), cobalt (1.4%), and Viabahn
(0.73%) across all bacterial combinations (P < .05). Pseudo-
monas aeruginosa achieved the greatest attachment at most
concentrations, regardless of the material. At the 24-hour
mark, the median attachment for each concentration was
greater than the highest initial concentration (108), with
nitinol and cobalt having a statistically signiﬁcant lower
attachment (P < .05).
Conclusions: Initial attachment is consistently poor,
regardless of inoculation concentration, but greater on
the synthetic grafts compared with metal stents. However,
after 24 hours in a nutrient-poor environment, Staphylo-
coccus aureus and Pseudomonas aeruginosa are still able to
achieve full attachment throughout.
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Objectives: Using a novel murine arteriovenous ﬁstula
(AVF) model, we sought to study the changes in extracel-
lular matrix (ECM) during normal adaptation of the
venous limb of the maturing AVF.
Methods: AVF were created in C57BL/6 mice and
the venous limb was extracted at postoperative days
(POD) 1, 3, 7, 21, and 42. Specimens were analyzed by
RT-PCR, histology, and immunohistochemistry (IHC).
Proteases, protease-inhibitors, collagens, glycoproteins,
and other noncollagenous proteins were characterized.
Results: Quantitative PCR demonstrated a signiﬁcant
ﬁvefold increase in matrix metalloproteinase (MMP)-9 and
a 200-fold increase in MMP-3 messenger (m)RNA expres-
sion at POD 1, and MMP-2 and MMP-12 by 15-fold and
100-fold, respectively, at POD 7. All tissue inhibitors of
metalloproteinases (TIMPs) mRNA expression were signif-
icantly increased at POD 21; TIMP1 was signiﬁcantly
increased by at least 10-fold at POD1-21. Collagens I,
III, and IV mRNA expression were increased signiﬁcantly
at POD7, with collagen III increasing earlier at POD3 by
10-fold. Fibronectin, perlecan, syndecan-2, versican, andvitronectin mRNA expression were all signiﬁcantly
increased at POD21. Fibrillin-1 and elastin were increased
at POD3 and 7. Thrombospondin-2 was signiﬁcantly
increased at POD7; osteopontin was increased nearly
200-fold at POD 1. IHC demonstrated this increased ex-
pression of MMPs, TIMPs, collagens I and III, osteopon-
tin, and ﬁbronectin at respective signiﬁcant time points;
EVG staining characterized elastin deposition at POD7.
Conclusions: Early ECM breakdown is initiated by
MMP-3, MMP-9, and TIMP1 in the ﬁrst few days after cre-
ation of AVF; MMP-2 and MMP-12 continue the early
ECMremodeling. At 1week, the foundation for remodeling
is establishedwith deposition of collagens I and III and ﬁbril-
lin-1 and Elastin. A transition phase begins with anti-angio-
genic thrombospondin-2 upregulation and all TIMPs
increased at POD21. A late-phase remodeling with larger
ECM proteins and glycoproteins is underway by POD21.
The remodeling of the venous limb of the AVF is character-
ized by early ECM breakdown and occurs in phases during
the ﬁrst 3 to 6 weeks after surgery.
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Objectives: The arteriovenous ﬁstula (AVF) is the gold
standard for hemodialysis access but continually exhibits
poor patency compared with other vascular constructs,
reﬂecting our imperfect understanding of ﬁstula maturation
and adaptation to the arterial circulation. We hypothesized
that the mouse AVF model reﬂects human AVF maturation
and that the shear stress ﬂowing through the AVF deter-
mines the maturation and patency of the ﬁstula.
Methods: The aortocaval AVF was created in C57Bl/6
mice using a 25-gauge needle. AVF patency and functional
status were determined using ultrasound, histology, blood
gas measurement, and molecular biological methods. Shear
stress was altered using 22-gauge and 28-gauge needles to
increase and decrease the shear stress, respectively.
Results: The mouse aortocaval ﬁstula showed three
distinct phases after a technically successful procedure. In
the immediate phase (days 0-1), 23.5% showed occlusion
due to thrombosis. The maturation phase (days 2-21) was
characterized by a slight increase of AVF patency from
76.5% (day 1) to 80.1% (day 21) and increased inferior
vena cava diameter by 49%. The failure phase (days 21-42)
showed neointimal hyperplasia and occlusion in 33% of the
mature AVFs. Shear stress in aortae proximal to AVFs
created with the 22-gauge needle was increased by 109%
Fig.
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was normalized by day 7. Patency was 100% and survival was
diminished by 50% in these large AVFs. Shear stress in AVFs
created with the 28-gauge needle was decreased by 39% but
AVF patency was reduced 50%. Survival was 100%.
Conclusions: This murine aortocaval model faithfully
recapitulates the maturation and failure phases of the human
AVF; this is the ﬁrst animal model to show these distinct
phases. Shear stress varies according to the diameter of the
ﬁstula. and AVF patency depends on the AVF shear stress.
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Objectives: Contrast-induced nephropathy (CIN) is the
third leading cause of hospital-acquired renal failure. Early
diagnosis and treatment of CIN may prevent signiﬁcant
sequelae. It has been reported that urinary ﬁbrinogen (Fg)
can be used as a biomarker of ischemia-reperfusion injury in
kidney. The objective of this study was to investigate whether
urinary Fg can serve as a biomarker for the diagnosis of CIN.
Methods: C57B1/6J mice received a prostaglandin
synthesis inhibitor (indomethacin, 10 mg/kg) and a nitric
oxide synthase inhibitor (Nu-Nitro-L-arginine methyl ester,
10 mg/kg) intraperitoneally (i.p.), before being given iodix-
anol in low-dose (6.24 g iodine/mL i.p.) and high-dose
(12.48 g iodine/kg i.p.) groups. Mice in the control group
received normal saline instead of iodixanol. Urine samples
were collected for Fg and creatinine (Cr) analysis using an
enzyme-linked immunosorbent assay kit. Kidneys were har-
vested 24 hours later. RNA was extracted from half of a kid-
ney specimen. Quantitative RT-PCR was used to quantify
Fg-a RNA expression, with glyceraldehyde-3-phosphate de-
hydrogenase as the endogenous control. The other half of
the kidney specimen was ﬁxed with formalin, embedded in
parafﬁn, and then stained with hematoxylin and eosin
(H&E) for histopathologic evaluation.
Results: H&E stain demonstrated mild renal injury in
the low-dose group, scoring from 0 to 1, and moderate
renal injury in high-dose group scoring from 1 to 2, based
on a pathologic grading scale of 0 to 3. Urinary Fg
increased signiﬁcantly from 0.37 6 0.13 mg/mg Cr in
the control group to 3.46 6 2.89 mg/mg Cr in the
low-dose group (P < .05) and 6.15 6 2.51 mg/mg Cr
in the high-dose group (P < .01). Fg-a RNA level
increased 40% in high-dose group compared with the con-
trol (P < .05), although no signiﬁcant changes were
detected in the low-dose group.Conclusions: Urinary Fg level increases are consistent
with the pathologic severity of CIN in animal models.
These results suggest that urinary Fg may be a potential
biomarker for early diagnosis of CIN. Further investigation
in clinical patients is needed.
Author Disclosures: H. Dong: Nothing to disclose; S.
Yang: Nothing to disclose; L. Yao: Nothing to disclose; W.
W. Zhang: Nothing to disclose; C. Zhao: Nothing to
disclose.
PS228.
Can Edaravone Protect Kidney Damage Caused by
Myonephropathic Metabolic Syndrome in Rats?
Mitsuhiro Yamamaura, Yuji Miyamoto, Masataka Mitsuno,
Hiroe Tanaka, Masaaki Ryomoto, Shinya Fukui.
Department of Cardiovascular Surgery, Hyogo College of
Medicine, Nishinomiya, Japan
Objectives: Free radicals have been implicated in myo-
nephropathic metabolic syndrome (MNMS), which dam-
ages not only muscles but also kidneys. At Vascular
Annual Meeting (VAM) 2012, we reported the free radical
scavenger, edaravone (Radicut, Mitsubishi Tanabe Pharma
Co, Japan), suppresses muscle injury by MNMS. In this
study, we evaluated whether edaravone can suppress kidney
damage by MNMS.
Methods: Lewis male rats (508 6 31 g, n ¼ 10)
were intraperitoneally injected with 3.0 mg/kg of edar-
avone (edaravone group [n ¼ 4]), or saline (MNMS
group [n ¼ 6]). The MNMS models were induced by
clamping the bilateral common femoral arteries for 5
hours and then declamping. Five hours after declamping,
the both kidneys were stained with hematoxylin and
eosin (Fig). Normal kidneys were harvested as a control
(n ¼ 3). Kidney damage was evaluated by the number of
cells in the glomerulus (glomerulus inﬁltration) and by
the number of residual tubular cells (enlargement of
tubular cells).
Results: The number of cells in the glomerulus was
signiﬁcantly increased in the MNMS group compared
with the control (77.2 6 10.3 vs 49.6 6 2.8 cells/
glomerulus, P < .01). The number of cells in the
